A couple of things....I'd like ADO to do well but... Has anybody...

A couple of things....I'd like ADO to do well but...

Has anybody got a good positive chart on ado that can provide some support to the ever increasingly fragile  FA chirped on about here? I have one but its not pretty with support levels being tested like they are right now..

Some quite blunt, difficult and not so promising  messages for all in the report including:

• We estimate positive cash flow in 2017
• We suggest 2018 is more likely to be the year of strong positive cash flow given the slow development path with large pathology and point of care customers.
• Mix&Go reaching $45mby 2020 is a stretch
• Small financial resources vs. incumbents
• Have overpromised in the past (slower partner uptake)
• A lot of projects across many regions with small team
• Large bioscience customers do not change suppliers quickly
• Large peers lower prices on consumables for existing tests
• Other reagents developed which compete with Mix&Go

Looks to me to be quite some time before ADO will become cash flow positive and i think we all know what that may mean.

While I have no idea if they are, I'm  still perturbed by the possibility that staff may be selling their shares..I would hope they are not..